BCG040: A Novel B7-H4 Biparatopic ADC for Heterogeneous Tumors
B7-H4 Biparatopic ADC Strategy for Receptor Clustering and Internalization
- Addressing resistance in epithelial tumors: B7-H4 (VTCN1) is widely overexpressed across aggressive epithelial malignancies. BCG040 is engineered as a biparatopic ADC to potentially address resistance-associated therapeutic challenges by enhancing target engagement and promoting receptor clustering.
- Biparatopic-driven receptor clustering: BCG040 is designed to simultaneously bind two non-overlapping epitopes on B7-H4, enhancing affinity and driving receptor cross-linking on the tumor cell surface.
- Enhanced trafficking and payload delivery: Through dual-epitope engagement, BCG040 is designed to promote accelerated intracellular trafficking and lysosomal delivery, supporting effective ADC payload release in B7-H4-positive tumor cells.
- Competitive differentiation: BCG040 is a differentiated B7-H4-targeting biparatopic ADC designed to enhance B7-H4 engagement, promote receptor clustering, and improve intracellular payload delivery in therapy-resistant epithelial tumors.
RenLite® Fully Human Common Light Chain Antibody Backbone
Built on the
RenLite® platform, BCG040 utilizes
common light chain technology to eliminate heavy/light chain mispairing, ensure seamless assembly, simplify manufacturing, and provide a developable antibody backbone for the B7-H4 biparatopic ADC drug development.
Proprietary BLD1102 Linker–Payload Design for ADC Drug Development
BCG040 is conjugated with Biocytogen's proprietary BLD1102 linker–payload system containing BCPT02, a topoisomerase I (TOP1) inhibitor payload designed to drive potent ADC-mediated cytotoxicity in solid tumor drug development.
- Payload-driven cytotoxic coverage: BCPT02 combines high payload potency with strong bystander killing to eliminate both target-positive and neighboring tumor cells.
- Developability-oriented linker design: BLD1102 linker is designed for superior hydrophilicity, controlled payload release, and high circulation stability, enhancing ADC developability and therapeutic performance.
Excellent Preclinical Performance
- BCG040 demonstrated nanomolar affinity for B7-H4, with full cross-reactivity to human/cynomolgus B7-H4 and minimal off-target binding to other B7 family members (Figure 1).
- BCG040 exhibited stronger binding and faster internalization than both analogs in breast (SK-BR-3) and ovarian (OVCAR3) cancer cells (Figure 2).
- In breast cancer PDX model, a single dose (1 mg/kg) of BCG040 showed sustained tumor regression (~40 days) and superior efficacy (Figure 3).
- BCG040 showed a favorable pharmacokinetic (PK) profile and developability characteristics, without body weight loss observed in the tested models (Figure 4).
Potential Indications
BCG040 is being evaluated as a B7-H4-targeting biparatopic ADC drug development asset for epithelial malignancies. Potential development areas include ovarian, breast, biliary tract and pancreatic cancers.
Preclinical Data Highlights Supporting BCG040 B7-H4 Biparatopic ADC Drug Development
The supporting preclinical data package for BCG040, generated from Biocytogen internal preclinical studies, includes SPR-based binding affinity, internalization, in vivo efficacy in PDX models, and pharmacokinetic (PK) evaluation. Together, these data support the development of BCG040 as a differentiated B7-H4-targeting biparatopic ADC for heterogeneous solid tumors.
BCG040 Demonstrates Nanomolar Affinity and B7-H4 Cross-Reactivity
Figure 1. Surface plasmon resonance (SPR)-based affinity analysis of BCG040 binding to B7-H4. BCG040 demonstrated strong binding to human, cynomolgus monkey, and mouse B7-H4, with KD values of 3.34E-12 M, 3.93E-12 M, and 5.38E-11 M, respectively. This cross-reactivity profile, together with stronger affinity than the Hu2F7 and SGN-B7H4V benchmark analogs, supports enhanced target engagement for B7-H4 biparatopic ADC development. In addition, no off-target binding to other B7 family members was observed.
BCG040 Shows Enhanced Internalization in Breast and Ovarian Cancer Cells
Figure 2. Internalization kinetics of BCG040 B7-H4 antibody backbone compared with benchmark B7-H4 antibody analogs. BCG040 (naked) showed faster internalization than both benchmark analogs in breast (SK-BR-3) and ovarian (OVCAR3) cells, supporting the biparatopic B7-H4 antibody design for accelerated intracellular trafficking and ADC payload delivery. In addition, BCG040 (naked) exhibited stronger binding activity than the benchmark analogs in these tumor cell models.
BCG040 Demonstrates Robust and Sustained Antitumor Efficacy in Breast Cancer PDX Models
Figure 3. Antitumor efficacy of BCG040 B7-H4 biparatopic ADC in breast cancer PDX models. A single dose of BCG040 at 1 mg/kg induced sustained tumor regression for approximately 40 days in breast cancer PDX models. BCG040 significantly suppressed tumor growth and outperformed benchmark B7-H4 ADC analogs, including Hu2F7, SGN-B7H4V, and FPA150 (conjugated with MMAE or BCPT02), demonstrating robust in vivo efficacy. In addition, no body weight loss was observed in any of the mouse models, supporting the preliminary tolerability profile of BCG040. (Data are expressed as mean ± SEM.)
BCG040 Shows a Favorable Pharmacokinetic Profile
Figure 4. Pharmacokinetic (PK) profile of BCG040 B7-H4 biparatopic ADC in serum and tumor compartments in a breast cancer PDX model. Following a single administration of BCG040 at 1 mg/kg, concentration–time profiles were evaluated for total antibody (-Tab), intact ADC (-ADC), and released payload (-BCPT02) in both serum and tumor samples. BCG040 showed a favorable PK profile, with robust bloodstream stability and tumor accumulation, supporting systemic ADC stability and tumor delivery. Together with the observed antitumor efficacy and no apparent body weight loss in the tested models, this favorable PK profile supports the continued preclinical development of BCG040 as a B7-H4-targeting biparatopic ADC.
Explore BCG040 Partnership Opportunities
Biocytogen welcomes partnership discussions to further evaluate this B7-H4 biparatopic ADC asset.
Frequently Asked Questions (FAQs) About BCG040 B7-H4 Biparatopic ADC
1. What makes BCG040 different from conventional B7-H4 ADCs?
BCG040 is designed as a first-in-class, fully human B7-H4 biparatopic ADC that binds two non-overlapping epitopes on B7-H4. This dual-epitope design promotes affinity-driven receptor clustering, accelerated internalization, and enhanced intracellular trafficking, supporting efficient ADC payload delivery compared with conventional single-epitope B7-H4 ADC approaches.
2. Which tumor types may benefit from B7-H4-targeted ADC development?
B7-H4 (VTCN1) is overexpressed in multiple epithelial malignancies, including ovarian cancer, breast cancer, biliary tract cancer, and pancreatic cancer. These tumor types often present limited treatment options, therapeutic resistance, and heterogeneous antigen expression. By targeting B7-H4-positive tumor cells with a biparatopic ADC design, BCG040 is being evaluated as a potential ADC development candidate for selected B7-H4-expressing epithelial tumors.
3. How does the BLD1102 linker–payload system support BCG040 ADC activity?
BCG040 is conjugated with Biocytogen's proprietary BLD1102 linker–payload system containing BCPT02, a topoisomerase I (TOP1) inhibitor payload. The BLD1102 linker–payload design is engineered to support potent ADC-mediated cytotoxicity, controlled payload release, hydrophilicity, circulation stability, and overall ADC developability.
4. How does the RenLite® platform support BCG040 development?
BCG040 is built on Biocytogen's RenLite® common light chain technology, which supports fully human antibody generation and developable antibody backbone design. For BCG040, the RenLite-derived biparatopic antibody format enables dual-epitope B7-H4 recognition while supporting efficient antibody assembly, ADC engineering, and downstream developability.
5. Why is human/cynomolgus B7-H4 cross-reactivity important for BCG040 development?
Human/cynomolgus B7-H4 cross-reactivity supports translational preclinical evaluation by enabling species-relevant assessment of BCG040. Strong binding to both human and cynomolgus monkey B7-H4 highlights BCG040 as a promising B7-H4-targeting biparatopic ADC candidate for translational development.
